AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The stock's rise snapped a four-day losing streak.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.